Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.41
AZN's Cash to Debt is ranked lower than
76% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. AZN: 0.41 )
Ranked among companies with meaningful Cash to Debt only.
AZN' s 10-Year Cash to Debt Range
Min: 0.2  Med: 3.25 Max: N/A
Current: 0.41
Equity to Asset 0.33
AZN's Equity to Asset is ranked lower than
86% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
AZN' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.45 Max: 0.59
Current: 0.33
0.3
0.59
Interest Coverage 5.58
AZN's Interest Coverage is ranked lower than
87% of the 390 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2854.00 vs. AZN: 5.58 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s 10-Year Interest Coverage Range
Min: 5.58  Med: 12.94 Max: 100.5
Current: 5.58
5.58
100.5
F-Score: 4
Z-Score: 2.09
M-Score: -2.79
WACC vs ROIC
8.77%
8.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 8.09
AZN's Operating margin (%) is ranked higher than
51% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.92 vs. AZN: 8.09 )
Ranked among companies with meaningful Operating margin (%) only.
AZN' s 10-Year Operating margin (%) Range
Min: 8.19  Med: 23.23 Max: 38.09
Current: 8.09
8.19
38.09
Net-margin (%) 4.68
AZN's Net-margin (%) is ranked lower than
55% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. AZN: 4.68 )
Ranked among companies with meaningful Net-margin (%) only.
AZN' s 10-Year Net-margin (%) Range
Min: 4.73  Med: 17.55 Max: 29.72
Current: 4.68
4.73
29.72
ROE (%) 6.26
AZN's ROE (%) is ranked lower than
51% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.43 vs. AZN: 6.26 )
Ranked among companies with meaningful ROE (%) only.
AZN' s 10-Year ROE (%) Range
Min: 5.89  Med: 31.28 Max: 45.52
Current: 6.26
5.89
45.52
ROA (%) 2.15
AZN's ROA (%) is ranked lower than
56% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. AZN: 2.15 )
Ranked among companies with meaningful ROA (%) only.
AZN' s 10-Year ROA (%) Range
Min: 2.2  Med: 14.19 Max: 20.88
Current: 2.15
2.2
20.88
ROC (Joel Greenblatt) (%) 26.13
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.24 vs. AZN: 26.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 28.15  Med: 74.64 Max: 199.48
Current: 26.13
28.15
199.48
Revenue Growth (3Y)(%) -5.70
AZN's Revenue Growth (3Y)(%) is ranked lower than
82% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. AZN: -5.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AZN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -54.6  Med: 2.50 Max: 20
Current: -5.7
-54.6
20
EBITDA Growth (3Y)(%) -30.70
AZN's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 494 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. AZN: -30.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AZN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -40.9  Med: 8.50 Max: 24.7
Current: -30.7
-40.9
24.7
EPS Growth (3Y)(%) -48.80
AZN's EPS Growth (3Y)(%) is ranked lower than
94% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -48.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AZN' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.8  Med: 12.80 Max: 27.9
Current: -48.8
-48.8
27.9
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

AZN Guru Trades in Q3 2014

Steven Cohen 611,100 sh (+64.81%)
Mario Gabelli 41,900 sh (+3.71%)
Jim Simons 1,847,100 sh (+2.91%)
Manning & Napier Advisors, Inc 317,180 sh (+2.64%)
NWQ Managers 64,475 sh (unchged)
Murray Stahl 13,000 sh (unchged)
George Soros 150,000 sh (unchged)
Steven Cohen 400,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Pioneer Investments 227,221 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes Sold Out
Stanley Druckenmiller Sold Out
Jeremy Grantham Sold Out
David Dreman 117,003 sh (-0.70%)
John Hussman 173,500 sh (-22.37%)
Louis Moore Bacon 30,000 sh (-25.00%)
» More
Q4 2014

AZN Guru Trades in Q4 2014

Pioneer Investments 754,327 sh (+231.98%)
Jim Simons 2,287,900 sh (+23.86%)
NWQ Managers 66,440 sh (+3.05%)
Francis Chou 13,000 sh (unchged)
John Hussman 173,500 sh (unchged)
Murray Stahl 13,000 sh (unchged)
Louis Moore Bacon Sold Out
George Soros Sold Out
Steven Cohen 587,400 sh (-3.88%)
Manning & Napier Advisors, Inc 227,870 sh (-28.16%)
Mario Gabelli 19,900 sh (-52.51%)
David Dreman 28,764 sh (-75.42%)
» More
Q1 2015

AZN Guru Trades in Q1 2015

Jim Simons 3,154,400 sh (+37.87%)
Pioneer Investments 758,498 sh (+0.55%)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Francis Chou 13,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
David Dreman 27,489 sh (-4.43%)
NWQ Managers 52,265 sh (-21.34%)
Mario Gabelli 11,800 sh (-40.70%)
John Hussman 52,000 sh (-70.03%)
Steven Cohen 61,800 sh (-89.48%)
» More
Q2 2015

AZN Guru Trades in Q2 2015

NWQ Managers 153,255 sh (+486.45%)
Murray Stahl 26,000 sh (+300.00%)
Jim Simons 3,934,600 sh (+149.47%)
Pioneer Investments 759,059 sh (+100.15%)
Francis Chou 13,000 sh (+100.00%)
John Hussman 42,000 sh (+61.54%)
Steven Cohen 50,200 sh (unchged)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Steven Cohen Sold Out
David Dreman Sold Out
Mario Gabelli 4,200 sh (-28.81%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about AstraZeneca PLC

Francis Chou Doubles Stake in AstraZeneca
Francis Chou (Trades, Portfolio) of Chou Associates Management runs a concentrated portfolio of just 22 stocks, trading in only two of them during the second quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 67.74
AZN's P/E(ttm) is ranked lower than
79% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.60 vs. AZN: 67.74 )
Ranked among companies with meaningful P/E(ttm) only.
AZN' s 10-Year P/E(ttm) Range
Min: 6.04  Med: 12.36 Max: 99.47
Current: 67.74
6.04
99.47
Forward P/E 8.02
AZN's Forward P/E is ranked higher than
69% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.47 vs. AZN: 8.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 68.20
AZN's PE(NRI) is ranked lower than
79% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. AZN: 68.20 )
Ranked among companies with meaningful PE(NRI) only.
AZN' s 10-Year PE(NRI) Range
Min: 6.02  Med: 12.36 Max: 99.72
Current: 68.2
6.02
99.72
P/B 4.43
AZN's P/B is ranked lower than
64% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. AZN: 4.43 )
Ranked among companies with meaningful P/B only.
AZN' s 10-Year P/B Range
Min: 2.3  Med: 3.82 Max: 6.97
Current: 4.43
2.3
6.97
P/S 3.17
AZN's P/S is ranked lower than
51% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. AZN: 3.17 )
Ranked among companies with meaningful P/S only.
AZN' s 10-Year P/S Range
Min: 1.61  Med: 2.40 Max: 3.9
Current: 3.17
1.61
3.9
PFCF 39.22
AZN's PFCF is ranked higher than
52% of the 274 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.71 vs. AZN: 39.22 )
Ranked among companies with meaningful PFCF only.
AZN' s 10-Year PFCF Range
Min: 6.59  Med: 13.40 Max: 41.6
Current: 39.22
6.59
41.6
POCF 17.25
AZN's POCF is ranked higher than
72% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.63 vs. AZN: 17.25 )
Ranked among companies with meaningful POCF only.
AZN' s 10-Year POCF Range
Min: 5.35  Med: 8.64 Max: 18.56
Current: 17.25
5.35
18.56
EV-to-EBIT 55.48
AZN's EV-to-EBIT is ranked lower than
81% of the 491 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.81 vs. AZN: 55.48 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5  Med: 9.30 Max: 55.7
Current: 55.48
4.5
55.7
Shiller P/E 15.10
AZN's Shiller P/E is ranked higher than
85% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. AZN: 15.10 )
Ranked among companies with meaningful Shiller P/E only.
AZN' s 10-Year Shiller P/E Range
Min: 8.05  Med: 13.54 Max: 25.03
Current: 15.1
8.05
25.03
Current Ratio 0.86
AZN's Current Ratio is ranked lower than
92% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. AZN: 0.86 )
Ranked among companies with meaningful Current Ratio only.
AZN' s 10-Year Current Ratio Range
Min: 0.64  Med: 1.50 Max: 2.03
Current: 0.86
0.64
2.03
Quick Ratio 0.72
AZN's Quick Ratio is ranked lower than
88% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. AZN: 0.72 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s 10-Year Quick Ratio Range
Min: 0.54  Med: 1.28 Max: 2.03
Current: 0.72
0.54
2.03
Days Inventory 137.05
AZN's Days Inventory is ranked lower than
62% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.99 vs. AZN: 137.05 )
Ranked among companies with meaningful Days Inventory only.
AZN' s 10-Year Days Inventory Range
Min: 88.45  Med: 148.49 Max: 291.09
Current: 137.05
88.45
291.09
Days Sales Outstanding 101.02
AZN's Days Sales Outstanding is ranked lower than
69% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.80 vs. AZN: 101.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s 10-Year Days Sales Outstanding Range
Min: 52.89  Med: 81.08 Max: 127.8
Current: 101.02
52.89
127.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.42
AZN's Dividend Yield is ranked higher than
92% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. AZN: 4.42 )
Ranked among companies with meaningful Dividend Yield only.
AZN' s 10-Year Dividend Yield Range
Min: 1.89  Med: 4.42 Max: 7.64
Current: 4.42
1.89
7.64
Dividend Payout 3.00
AZN's Dividend Payout is ranked lower than
80% of the 394 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. AZN: 3.00 )
Ranked among companies with meaningful Dividend Payout only.
AZN' s 10-Year Dividend Payout Range
Min: 0.23  Med: 0.89 Max: 4.87
Current: 3
0.23
4.87
Dividend growth (3y) -2.00
AZN's Dividend growth (3y) is ranked lower than
65% of the 255 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. AZN: -2.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
AZN' s 10-Year Dividend growth (3y) Range
Min: -4.5  Med: 11.10 Max: 28.3
Current: -2
-4.5
28.3
Yield on cost (5-Year) 6.00
AZN's Yield on cost (5-Year) is ranked higher than
92% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.64 vs. AZN: 6.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.57  Med: 6.00 Max: 10.37
Current: 6
2.57
10.37
Share Buyback Rate 2.60
AZN's Share Buyback Rate is ranked higher than
97% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. AZN: 2.60 )
Ranked among companies with meaningful Share Buyback Rate only.
AZN' s 10-Year Share Buyback Rate Range
Min: 4.6  Med: 2.00 Max: -144.8
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.28
AZN's Price/Projected FCF is ranked higher than
78% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.70 vs. AZN: 1.28 )
Ranked among companies with meaningful Price/Projected FCF only.
AZN' s 10-Year Price/Projected FCF Range
Min: 0.5  Med: 1.18 Max: 5.78
Current: 1.28
0.5
5.78
Price/Median PS Value 1.32
AZN's Price/Median PS Value is ranked lower than
53% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. AZN: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
AZN' s 10-Year Price/Median PS Value Range
Min: 0.69  Med: 1.23 Max: 2.44
Current: 1.32
0.69
2.44
Earnings Yield (Greenblatt) (%) 1.79
AZN's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. AZN: 1.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AZN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.78  Med: 10.80 Max: 22.3
Current: 1.79
1.78
22.3
Forward Rate of Return (Yacktman) (%) -15.17
AZN's Forward Rate of Return (Yacktman) (%) is ranked lower than
87% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.88 vs. AZN: -15.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AZN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -17.3  Med: 18.40 Max: 27.7
Current: -15.17
-17.3
27.7

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 24,711 24,156 25,456 24,663
EPS($) 4.07 4.02 4.47 4.78
EPS without NRI($) 4.07 4.02 4.47 4.78

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZN.UK, ZEG.Germany, AZN.Argentina, AZNN.Mexico, OXAZN.Switzerland, AZNCF.USA, ZEGA.Germany, AZNDF.USA,
AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 

More From Other Websites
AstraZeneca's Brilinta Gains FDA Nod for Label Expansion Sep 04 2015
AstraZeneca: filling a hole Sep 04 2015
3 FTSE 100 Buys You Won’t Regret: Lloyds Banking Group PLC, AstraZeneca plc And Rolls-Royce... Sep 04 2015
3 FTSE 100 Buys You Won't Regret: Lloyds Banking Group PLC, AstraZeneca plc And Rolls-Royce Holdings... Sep 04 2015
AstraZeneca to Update on Leading Lung Cancer Portfolio at WCLC 2015 Sep 04 2015
AstraZeneca wins FDA approval for expanded use of blood thinner Sep 04 2015
AstraZeneca wins U.S. approval for longer use of blood thinner Sep 04 2015
AstraZeneca wins U.S. approval for longer use of blood thinner Sep 04 2015
London pre-open: Weak start expected ahead of US jobs report Sep 04 2015
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015 Sep 04 2015
Europe midday: Shares drop as investors eye US jobs report Sep 03 2015
FDA approves longer-term use of AstraZeneca blood thinner Sep 03 2015
FDA approves longer-term use of AstraZeneca blood thinner Sep 03 2015
US FDA Approves Expanded Indication For BRILINTA To Include Long-Term Use In Patients With A History... Sep 03 2015
FDA approves expanded indication for AstraZeneca's blood thinner Sep 03 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history... Sep 03 2015
5:03 pm AstraZeneca announces that the FDA has approved BRILINTA tablets at a new 60mg dose to be... Sep 03 2015
Does Recent Weakness At Lloyds Banking Group PLC, Reckitt Benckiser Group Plc & AstraZeneca plc Make... Sep 03 2015
Does Recent Weakness At Lloyds Banking Group PLC, Reckitt Benckiser Group Plc & AstraZeneca plc Make... Sep 03 2015
AstraZeneca Ties Up for FluMist, CAZ-AVI Scores; Shares Up Sep 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK